Evercore Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Evercore Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-600	Closed	-$239K	–	420
2025 Q4	$239K	Hold	600	–	–	﹤0.01%	371
2025 Q3	$274K	Buy	+600	New	+$244K	﹤0.01%	360
2023 Q1	–	Sell	-899	Closed	-$214K	–	406
2022 Q4	$214K	Buy	+899	New	+$192K	﹤0.01%	381
2018 Q1	–	Sell	-600	Closed	-$76K	–	370
2017 Q4	$76K	Hold	600	–	–	﹤0.01%	512
2017 Q3	$70K	Hold	600	–	–	﹤0.01%	524
2017 Q2	$48K	Hold	600	–	–	﹤0.01%	581
2017 Q1	$31K	Hold	600	–	–	﹤0.01%	679
2016 Q4	$22K	Hold	600	–	–	﹤0.01%	738
2016 Q3	$41K	Hold	600	–	–	﹤0.01%	639
2016 Q2	$33K	Sell	600 -300	-33%	-$18.9K	﹤0.01%	660
2016 Q1	$57K	Hold	900	–	–	﹤0.01%	543
2015 Q4	$84K	Buy	900 +600	+200%	+$55.6K	﹤0.01%	501
2015 Q3	$24K	Hold	300	–	–	﹤0.01%	704
2015 Q2	$36K	Hold	300	–	–	﹤0.01%	687
2015 Q1	$31K	Hold	300	–	–	﹤0.01%	706
2014 Q4	$29K	Hold	300	–	–	﹤0.01%	618
2014 Q3	$23K	Hold	300	–	–	﹤0.01%	713
2014 Q2	$19K	Hold	300	–	–	﹤0.01%	742
2014 Q1	$20K	Buy	+300	New	+$23.2K	﹤0.01%	738

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Evercore Wealth Management's ALNY Position: Q1 2026 in Review

Evercore Wealth Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 600 shares — an estimated $239K sold.

Evercore Wealth Management first reported a position in ALNY in Q1 2014 and held it in 19 quarters. The position peaked at $274K in Q3 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Evercore Wealth Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Evercore Wealth Management sold 600 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $239K.
Evercore Wealth Management first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 19 quarters.
Evercore Wealth Management's Alnylam Pharmaceuticals position peaked at $274K in Q3 2025.
791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Evercore Wealth Management's 13F filing for Q1 2026, filed 15 May 2026.